Glycogen synthase kinase-3 (GSK-3) is a serine/threonine protein kinase which is an important regulator of glycogen synthesis in skeletal muscle [1] [2] [3] . In mammals two genes encode the closely related proteins termed 5] . The molecular mechanisms by which the activity of GSK-3 is regulated include constitutive activation through tyrosine phosphorylation on Tyr 216 [6] , and a 50-70 % inactivation in response to insulin and growth factors by the phosphorylation of GSK-3a on Ser 21 and GSK-3b on Ser 9 [7] [8] [9] [10] . This inhibition of GSK-3 activity by phosphorylation in response to insulin and growth factors seems to be mediated predominantly by protein kinase B (Akt/RAC) since inhibitors of the p90 rsk and p70 s6 k involving pathways have no effect on the level of GSK-3 inactivation (10). The inactivation of GSK, however, can be blocked by incubation with the phosphatidylinositol 3-kinase (PI 3 -kinase) inhibitors wortmannin and LY 294 002 which also block insulin stimulated glycogen synthesis in various cell systems [11, 12] . In its active form GSK-3 inactivates glycogen synthase, the rate-limiting enzyme of glycogen synthesis, by phosphorylation of site 3a-3 c and site 4, and since GSK-3 is constitutively active it inhibits glycogen synthesis in the insulin deficient state [6, 13] . Glycogen synthase is also activated by dephosphorylation predominantly of site 3a-3 c and possibly of site 2 [1, 14] in response to insulin by the glycogen-associated form of protein phosphatase-1 (PP1G). The overall increase in glycogen synthesis upon insulin stimulation most likely results from the combined activation of PP1G and the inhibition of GSK-3 [15]. Studies of candidate genes for the Diabetologia (1997) Summary Activation of glycogen synthesis in skeletal muscle in response to insulin results from the combined inactivation of glycogen synthase kinase-3 (GSK-3) and activation of the protein phosphatase-1, changing the ratio between the inactive phosphorylated state of the glycogen synthase to the active dephosphorylated state. In a search for genetic defects responsible for the decreased insulin stimulated glycogen synthesis seen in patients with non-insulin-dependent diabetes mellitus (NIDDM) and their glucose-tolerant first-degree relatives we have performed mutational analysis of the coding region of the 2 isoforms of GSK-3a and GSK-3b in 72 NIDDM patients and 12 control subjects. No structural changes were detected apart from a few silent mutations. Mapping of the GSK-3a to chromosome 19q13.1-13.2 and the GSK-3b to chromosome 3q13.3-q21 outside known genetic loci linked to NIDDM further makes it unlikely that these genes are involved in the pathogenesis of common forms of NIDDM. [Diabetologia (1997) 40: 940-946] Keywords Southern hybridization, in situ hybridization, total RNA, skeletal muscle, RT-PCR-SSCP analysis, mutations, NIDDM. 
tivity by phosphorylation in response to insulin and growth factors seems to be mediated predominantly by protein kinase B (Akt/RAC) since inhibitors of the p90 rsk and p70 s6 k involving pathways have no effect on the level of GSK-3 inactivation (10) . The inactivation of GSK, however, can be blocked by incubation with the phosphatidylinositol 3-kinase (PI 3 -kinase) inhibitors wortmannin and LY 294 002 which also block insulin stimulated glycogen synthesis in various cell systems [11, 12] . In its active form GSK-3 inactivates glycogen synthase, the rate-limiting enzyme of glycogen synthesis, by phosphorylation of site 3a-3 c and site 4, and since GSK-3 is constitutively active it inhibits glycogen synthesis in the insulin deficient state [6, 13] . Glycogen synthase is also activated by dephosphorylation predominantly of site 3a-3 c and possibly of site 2 [1, 14] in response to insulin by the glycogen-associated form of protein phosphatase-1 (PP1G). The overall increase in glycogen synthesis upon insulin stimulation most likely results from the combined activation of PP1G and the inhibition of GSK-3 [15] . Studies of candidate genes for the potential involvement in the consistently reported decreased insulin stimulated muscle glycogen synthesis in NIDDM patients and their glucose-tolerant first degree relatives [16] [17] [18] would seem to be a relevant approach in the search for the genetic background for familial NIDDM. Potential candidate genes might hence be those encoding key proteins involved in the molecular signalling from the insulin receptor to glucose transporting molecules and/or to the glycogen synthase [19] .
Since the GSK-3 holds a key position in the cellular regulation of glycogen synthesis it is a logical candidate gene for the genetic basis of insulin resistance of muscle glycogen synthesis. Consequently, the objectives of the present study were: 1) to perform molecular scanning of the coding region of both isoforms (a/b) of GSK-3 on skeletal musle RNA isolated from NIDDM patients with reverse transcriptase polymerase chain reaction (RT-PCR) and single strand conformation polymorphism (SSCP) methodology in combination with heteroduplex analysis; and 2) to map the GSK-3 genes to their chromosomal loci for the estimation of their potential involvement in the forms of NIDDM that are linked to the NIDDM1 and NIDDM2 loci identified in NIDDM populations by genome wide genotyping [20, 21] .
Subjects and methods
Subjects. Seventy-two NIDDM patients and 12 healthy volunteers participated in the present investigation. All were Caucasians by self report. Physiological examinations were started in the fasting state at 08.00 after a 10 h overnight fast. The control subjects had normal fasting blood glucose levels and no family history of NIDDM. Subjects with NIDDM, as defined by the National Diabetes Group, were recruited from the outpatient clinic at Steno Diabetes Center. Before participation, the purpose and risks of the study were carefully explained both orally and in writing, and informed consent was obtained. The protocol was approved by the committee of ethics in Copenhagen County and was in accordance with the Helsinki declaration.
Probes. The cloning of the human GSK-3a and GSK-3b cDNAs into pBluescript vector has been previously described [6] . The 2.1 kb insert representing the GSK-3a and the 1.4 kb fragment encoding GSK-3b were gel purified and radiolabelled by random priming with 32 P-a-dCTP for Southern blot hybridization [22] . The entire plasmids were nick translated using digoxigenin-11-dUTP (Boehringer Mannheim, Mannheim, Germany) for fluorescence in situ hybridization.
Analysis of somatic cell hybrids. DNA isolated from the human × rodent hybrids was digested with Hind III and used to prepare Southern blots as described previously [23] . The hybrids designated with the GM prefix were obtained from the Human Genetic Mutant Cell Repository (Camden, N. J., USA) while those with the A 3 prefix were kindly provided by Dr. P. Pearson (John Hopkins University, Baltimore, Md., USA).
Fluorescence in situ hybridization. Chromosome preparations were obtained from phytohaemagglutinin-stimulated normal peripheral blood lymphocytes cultured for 72 h. Cytogenetic harvests and slide preparations were performed using standard methods. The slides were stored at -80°C before use.
Fluorescence in situ hybridization to metaphase chromosomes was performed as described [24] . Briefly the slides were denatured for 2 min in 70 % formamide/2 × SSC (pH 7.0) at 70°C and dehydrated in ice cold ethanol. The digoxigenin labelled probes (50-100 ng) were dissolved in hybridization mixture (50 % formamide, 10 % dextran sulfate, 2 × SSC plus 10 m g sheared salmon sperm DNA as carrier), denatured at 75°C for 5 min and applied to the slides. Hybridization was allowed to proceed overnight in a humid chamber at 37°C.
The slides were then washed using formamide-wash procedure using the fluorescein isothiocyanate (FITC)-digoxigenin and Texas Red-biotin detection kits and amplification protocol for dual color fluorescence in situ hybridization (FISH) (Oncor, Gaithersburg, Maryland, USA). Slides were counterstained by mounting the slides in an antifade solution containing 1 m g/ml phenylendiamine, propidium iodide and 4 ′,6-diamideino-2-phenylindole (DAPI). Metaphase spreads were examined and photographed using a Zeiss Axiophot microscope and the appropriate UV-filter combinations. The 35 mm slides were scanned using a Nikon Coolscan (Nikon, Melville, N. Y., USA), processed using Adobe Photoshop 3.0 (Adobe Photoshop, Windsor, Ontario, Canada) and printed using a Fujix Pictrography 3000 (Fuji Photofilm Europa, Dü sseldorf, GER). Chromosome identification was performed by simultaneous hybridization with the a -satellite repeat probe as well as by counter-staining the chromosomes with DAPI which produces a Q-banding pattern. In addition, metaphase spreads were G-banded using a post-fluorescence in situ hybridizaton banding technique [25] .
Mutational analyses. Total RNA was extracted from vastus lateralis muscle biopsies and cDNA synthesis was performed according to standard procedures. cDNAs encoding GSK-3b were amplified as described [26] in the following manner: denaturation at 95°C for 3 min followed by 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min and 30 s for 35 cycles, and finally extension at 72°C for 3 min. In this primary PCR a cDNA segment of 1328 bp was amplified, and secondary PCR was performed with incorporation of (a- Numbers indicate 5'end and 3' end of primers bio, Biotinylated PCR. In this way, the primary PCR was reamplified in six overlapping PCR segments ranging from 254 to 294 bp ( Table 1) .
The primary PCR reactions on GSK-3a were divided in two steps: first, from nucleotide position 88-872 the normal dGTP was substituted by the base analogue 7-deaza-2 ′-deoxyguanosine-5 ′-triphosphate, C 7 dGTP (Pharmacia P-L Biochemicals Inc., Milwaukee, Wis., USA) in order to amplify this heavily GC containing region (81 %). For this region a hot start procedure was applied with initial denaturation at 99°C for 10 min before adding the polymerase followed by 35 cycles at 95°C for 2 min, 65°C for 1 min, and 72°C for 2 min. Secondary PCR reactions were run following the same principles as for the GSK-3b, except with annealing temperatures of 65°C; for the segment 88-319, PCR reactions were optimized with Opti-Prime (Stratagene Inc, La Jolla, Calif., USA). In all, seven secondary segments were amplified from this region. Primary and secondary PCR reactions for GSK-3a nucleotide segment 806-1650 were run as described for the GSK-3b, and four DNA segments from this region were amplified ( Table 2) .
The secondary PCR samples were run on a non-denaturing polyacrylamide gels for SSCP and heteroduplex analysis as previously described [26] . SSCP/heteroduplex variants were sequenced using Sequenase 2.0 (US Biochemical, Cleveland, Ohio, USA) and (a- 
Results

Chromosomal mapping of GSK-3a and GSK-3b.
The chromosomal localization of the GSK-3a locus was determined by Southern blot analysis of DNA samples isolated from a panel of hamster or mouse × human somatic cell hybrids. The 2.1 kb GSK-3a cDNA hybridized to 5 Hind III fragments of approximately 23, 13, 7, 5.9 and 2.3 kb in size in human genomic DNA (Fig. 1 a) . The chromosomal localization was determined by scoring the presence or absence of the human specific bands on the autoradiograph of the Southern blot as demonstrated in Figure 1 a and summarized in Table 3 . In this set of hybrids only the presence or absence of chromosome 19 was concordant with GSK-3a hybridizations. Cross hybridization to both mouse and hamster DNA indicates the presence of homologous genes in these species. The chromosomal localization of the human GSK3a locus obtained by somatic cell hybrid mapping was independently confirmed and refined by fluorescence in situ hybridization. In these experiments we examined 54 metaphase spreads from normal lymphocytes for specific signals to be specific only if they were detected on each chromatid of a single chromosome. Specific signals were seen in 11 % of the metaphases examined. In each case the hybridization signals were located in the middle of the long arm of chromosome 19, i. e. 19q13.1-q13.2 ( Fig. 1 b) .
The chromosomal localization of the GSK-3b locus was performed as described for GSK-3a using a panel of hamster or mouse × human somatic cell hybrids. The 1.4 kb GSK-3b cDNA hybridized to 6 Eco-RI fragments of approximately 21, 13, 10.5, 6, 4.5 and 3.5 kb in size in human genomic DNA (Fig. 2 a) . The chromosomal localization was determined by scoring GM 10612  +  ------------------+ -----GM 10629  ------+ ------------------GM 10791  -------+ -----------------GM 10868  ------------+ ------------GM 10880  -+ -----------+ -+ ---------GM 10888  ----------------------+ --GM 10611 - the presence or absence of the human specific bands on the autoradiograph of the Southern blot as demonstrated in Figure 2 a and summarized in Table 4 . In this set of hybrids only the presence or absence of chromosome 3 was concordant with GSK-3b hybridizations. Cross hybridizations to both mouse and hamster DNA indicates the presence of homologous genes in these species.
As for the GSK-3a gene, the chromosomal localization of the human GSK-3b locus determined by somatic cell hybrid mapping was confirmed and refined by fluorescence in situ hybridization. In these experiments we examined 61 metaphase spreads from normal lymphocytes. Specific signals were seen in 30 % of the metaphase spreads examined. In each case the hybridization signals were located in the middle of the long arm of chromosome 3 in the region 3q13.3-q21 (Fig. 2 b) .
PCR-SSCP and heteroduplex analysis and nucleotide sequencing of GSK-3a and GSK-3b.
cDNA from 72 NIDDM patients and 12 healthy control subjects was analysed for genetic variations in the coding region of GSK-3a and GSK-3b. Two aberrant SSCP (heterozygous) profiles were detected of GSK-3a in 2 different cDNA segments in 2 different NIDDM patients (Table 5 ). In the case of GSK-3b one heterozygous SSCP profile, was detected in 3 different NID-DM patients in codon 76, codon 126, and codon 382 respectively (Table 5) . Furthermore, analysis of cDNA including the entire coding regions of GSK3a and GSK-3b in a total of 84 subjects did not reveal any alternatively spliced isoforms of the 2 GSK-3 cDNAs (data not shown).
Discussion
Several studies in various ethnic groups including Caucasians have shown that, together with hyperinsulinaemia, decreased insulin stimulated glycogen synthase activity and glycogen synthesis of skeletal muscle are the earliest detectable physiological abnormalities and predictors of future development of NIDDM [16] [17] [18] 27] . Furthermore, cultured skeletal myotubes and myoblasts or fibroblasts obtained from insulin resistant subjects or NIDDM patients are characterized by impaired insulin stimulated glycogen synthesis [28] [29] [30] . These physiological variables therefore most likely represent the phenotypic GM 10612  -------------------+ -----GM 10629  ------+ ------------------GM 10791  -------+ -----------------GM 10868  ------------+ ------------GM 10880  -+ -----------+ + ----------GM 10888  ----------------------+ --GM 10611 - expression of important parts of the genetic basis for subsets of NIDDM. Focusing on glycogen synthesis, we and others have previously reported reduced activity of glycogen synthase, but normal content of the enzyme, and a reduced expression of glycogen synthase mRNA in skeletal muscle of NIDDM patients [18, 31] . However, molecular dissection of the coding region and the putative promoter revealed no prevalent mutations in the glycogen synthase gene expressed in skeletal muscle [32, 33] . Since glycogen synthase is activated by dephosphorylation by the type 1 protein phosphatase in response to insulin, defective activation of glycogen synthesis might also be secondary to the reduced insulin stimulated activity of glycogen phosphatase and glycogen phosphorylase phosphatase [34, 35] . Performing mutational analysis in the Danish Caucasian NIDDM population we found no genetic defects with biological implications in the 3 catalytic subunits of type 1 protein phosphatase [36] . However, an E905Y polymorphism in the glycogenassociated subunit of the type 1 protein phosphatase (PP1G) was associated with insulin resistant glycogen synthesis and a compensatory hypersecretion of insulin in non-diabetic subjects [26] . The E905Y polymorphism of PP1G was not in itself associated with an increased prevalence of NIDDM among Caucasians of Danish ancestry [26] .
A parallel insulin mediated activation of glycogen synthase occurs through GSK-3 [10] [11] [12] 37] . Thus, GSK-3a and GSK-3b are important antagonists to the insulin stimulated disinhibition of the glycogen synthase as evidenced from recent studies in which a mutated constitutively active GSK inhibits glycogen synthesis when overexpressed in 293 cells [13] .
In the region of chromosome 19q13.3 where the GSK-3a maps, associations have been found in 3 different ethnic groups between markers in the glycogen synthase gene and NIDDM (38) (39) (40) (41) . This locus was, however, not genetically linked to NIDDM applying whole-genome scanning in Mexican-Americans, Pima Indians or Botnia Finns (20, 21, 42) . The finding of only silent polymorphisms in the GSK-3 cDNAs and no evidence for splice variants in the present study further narrows the number of known candidate genes that may be involved in the impaired insulin stimulated glycogen synthesis in skeletal muscle of NIDDM patients. However, since in the present study we have analysed only the coding regions of the GSK-3 genes we cannot exclude the presence of potentially functional mutations in the promoter regions. Finally, it is also worthwhile to point out that most gene variants so far identified in NIDDM populations have only been found in low frequencies (less than a few percent) and therefore this study does not have the power to detect variants of this magnitude.
